Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Biotechnology

Healthcare
$1.30 +3.57%

+$0.06 today

Market cap
$182.35M
Beta
0.97
P/E (TTM)
-3.4
EPS (TTM)
-$0.52
52W Low $1.33High $2.26

Volume 0.50M

Average 1.03M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$51.97M

FY 2025 · Annual

Net Income

-$48.26M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.1M123.44K260.5K00
Cost of Revenue11.36M6.72K13.62M26.27K0
Gross Profit(8.26M)116.72K(13.36M)(26.27K)0
Gross Margin-266.4%94.6%-5127.8%——
Research & Development11.36M12.03M13.62M17.21M29.79M
Selling, General & Admin06.21M6.73M11.38M23.56M
Operating Expenses6.51M18.25M6.73M28.56M51.97M
Depreciation & Amortization14.77M6.72K177.4K26.27K60.5K
EBITDA0(18.05M)(18.85M)(27.49M)(53.29M)
EBITDA Margin0.0%-14620.4%-7236.7%——
Operating Income(14.77M)(18.13M)(20.09M)(28.59M)(51.97M)
Operating Margin-476.2%-14686.2%-7712.0%——
Interest Income19.92K74.45K1.06M1.07M3.72M
Interest Expense19.92K74.45K000
Other Income / Expenses(19.92K)74.45K1.06M1.07M3.72M
Income Before Tax(14.79M)(18.05M)(19.03M)(27.52M)(48.26M)
Pre-Tax Margin-476.9%-14625.9%-7304.8%——
Income Tax Expense00000
Net Income(14.79M)(18.05M)(19.03M)(27.52M)(48.26M)
Net Margin-476.9%-14625.9%-7304.8%——
EPS (Basic)(4.88)(4.26)(3.57)(1.16)(0.49)
EPS (Diluted)(4.88)(4.26)(3.57)(1.16)(0.49)
Weighted Avg Shares3.03M4.2M5.33M69.36M98.31M
Weighted Avg Shares (Diluted)3.03M4.2M5.33M69.36M98.31M

IKT Earnings Waterfall · TTM

NASDAQ:IKT · Revenue to Net Income

Key Ratios

EPS$-0.54
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.5
P/S Ratio0.0

Analysis

$0 of revenue converted into -$51.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.54, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 10, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipOct 21, 2026
3Initial statement of beneficial ownershipOct 21, 2026
8-KCurrent reportOct 20, 2026

How much revenue does IKT generate?

Inhibikase Therapeutics, Inc. (IKT) reported $0.00 of revenue in fiscal 2025.

Is IKT profitable?

Inhibikase Therapeutics, Inc. (IKT) reported -$48.26M of net income.